Developing Transformative Medicines to Restore Health and Improve Patients’ Lives
Potential to reduce the risk of disease progression.
Lessen symptom burden.
Provide greater hope for significantly better health.
It all adds up to more treasured time with family and friends, and motivation to pursue lifelong dreams and passions, and additional milestones reached.
At CymaBay, we are driven by our relentless commitment to restoring health and improving the lives of people with chronic liver, metabolic, and inflammatory diseases through innovative treatments that enhance quality of life and overall disease progression.
We understand the urgent need for better treatments now. Each day matters to patients and families affected by these conditions.
We focus on identifying and targeting unique mechanisms involved in inflammation and fibrosis, with the goal of raising the standard of care for treatment that impacts patients and the families who support them.
Our lead product candidate, seladelpar, is being developed for primary biliary cholangitis (PBC), an autoimmune disease that destroys the small bile ducts of the liver. The hallmark of PBC is impaired bile flow (cholestasis), which over time leads to liver damage (inflammation and fibrosis). People living with PBC often have debilitating symptoms including fatigue, itching (pruritus), and sleep disturbance. In later stages, cirrhosis, liver failure, and liver transplantation are inevitable.
